Bristol-Myers: quarterly EPS above expectations

(CercleFinance.com) - Pharmaceutical giant Bristol-Myers Squibb has reported Q4 2018 adjusted EPS that is up 38% at 94 cents, i.
e. ten cents above the consensus, on revenues that are up 10% to nearly six billion dollars.

The company's FY EPS reached 3.98 dollars, exceeding its target range provided three months ago (3.80 dollars to 3.90 dollars), with sales growth of 9%, in line with its forecast for high single-digit growth.

“We are beginning 2019 with good momentum in our current business, with Opdivo and Eliquis continuing as strong and growing franchises,” said Giovanni Caforio, Bristol-Myers Squibb's chairman and chief executive officer, who has set a FY EPS target range of 4.10-4.20 dollars.


Copyright (c) 2019 CercleFinance.com. All rights reserved.